Antioxidant Activity in Pulp and Peel of Three Mango Varieties

The aim of the present study was to estimate the content of total polyphenols and flavonoids and to investigate in-vitro antioxidant potential of methanolic extracts of peel and pulp in three Indian mango varieties. Antioxidant activity was assessed using [2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)] ABTS+ assay, 2,2-diphenyl-1-picryl-hydrazyl (DPPH) assay, ferric-reducing ability of plasma (FRAP) assay, and phosphomolybdate assay for Total Antioxidant Capacity (TAC). Total phenolic and flavonoid content was also determined, and expressed in gallic acid equivalent (GAE) and quercetin equivalent (QE), respectively. Results of this study indicated that methanolic extracts of mango peel had significantly higher antioxidant activity compared to that of pulp (29.69 and 3.12), irrespective of the method or variety used. Free radical scavenging and antioxidant activity may be attributed to presence of phenolic (24.61mg GAE/g DM in the peel and 2.01mg GAE/g DM in the pulp) and flavonoid compounds (24.95mg QE/g DM in the peel and 16.15mg E/g DM in the pulp). Antioxidant activity determined by ABTS, DPPH and FRAP assays in mango peel was significantly higher than in the mango pulp (24.95 1.96mg TE /g DM, 23.68 versus 4.60mg BHA/g DM and 40.52 versus 2.781mg TE/g DM), respectively. Results for scavenging activity against DPPH were 96.18% for the peel and 23.86% for the pulp, while, free radical scavenging activity results using ABTS+ assay were 99.62% in the peel and 13.46% in the pulp. Our study justifies research in processing of mango peel into useful, functional food ingredients (powders or extracts)

Gender differences in outcomes of patients with cystic fibrosis

Background: Cystic fibrosis (CF) is a common life-shortening genetic disease in which women have been described to have worse outcomes than males, particularly in response to respiratory infections with Pseudomonas aeruginosa. However, as advancements in therapies have improved life expectancy, this gender disparity has been challenged. The objective of this study is to examine whether a gender-based survival difference still exists in this population and determine the impact of common CF respiratory infections on outcomes in males versus females with CF. Methods: We conducted a retrospective cohort analysis of 32,766 patients from the United States Cystic Fibrosis Foundation Patient Registry over a 13-year period. Kaplan-Meier and Cox proportional hazards models were used to compare overall mortality and pathogen based survival rates in males and females. Results: Females demonstrated a decreased median life expectancy (36.0 years; 95% confidence interval [CI] 35.0–37.3) compared with men (38.7 years; 95% CI 37.8–39.6; p<0.001). Female gender proved to be a significant risk factor for death (hazard ratio 2.22, 95% CI 1.79–2.77), despite accounting for variables known to influence CF mortality. Women were also found to become colonized earlier with several bacteria and to have worse outcomes with common CF pathogens. Conclusions: CF women continue to have a shortened life expectancy relative to men despite accounting for key CF-related comorbidities. Women also become colonized with certain common CF pathogens earlier than men and show a decreased life expectancy in the setting of respiratory infections. Explanations for this gender disparity are only beginning to be unraveled and further investigation into mechanisms is needed to help develop therapies that may narrow this gender gap